undetectable viral load

Related by string. * Undetectable : previously undetectable steroid . undetectable steroids . undetectable HCV RNA . undetectable steroid . undetectable HGH / VIRAL . Virals . Viral . virals : viral load . viral loads . inhibit viral replication . viral infection . viral infections / LOA . LOAD . LoA . Load : load balancing . Waste Allocation Load . load balancer . unscheduled load shedding * *

Related by context. All words. (Click for frequent words.) 74 undetectable HCV RNA 72 copies mL 72 virologic failure 71 viral suppression 71 HBeAg seroconversion 71 copies ml 70 virologic response 69 sustained virologic response 69 viral load 68 virologic suppression 68 complete cytogenetic response 68 viral loads 67 undetectable viral loads 67 detectable HCV RNA 67 undetectable HBV DNA 67 HBV DNA 67 HIV RNA 67 seroconversion 66 ACR# response 66 sustained virological response 66 log# reduction 66 virological suppression 65 LEXIVA r 65 adefovir 65 HCV RNA 64 complete cytogenetic 64 HBV DNA levels 64 ribavirin therapy 64 CCyR 64 rapid virologic response 64 IU mL 64 virological failure 64 sUA 64 achieved ACR# 64 peginterferon alfa 2a 64 #mg dose [002] 64 peginterferon 63 TDF FTC 63 entecavir 63 median CD4 63 experienced virologic failure 63 virologic response EVR 63 virological response 63 abacavir lamivudine 63 protease inhibitor PI 63 HbA1c levels 63 SVR# 63 LPV r 63 median PFS 63 seroprotection 63 PASI scores 63 A1c levels 62 adalimumab 62 PREZISTA r 62 Pegasys plus Copegus 62 NNRTI resistance 62 HCV genotype 1 62 CD4 cell 62 Hb A1C 62 coinfected 62 fosamprenavir 62 CD4 counts 62 darunavir 62 IU ml 62 evaluable subjects 62 biochemical relapse 62 tipranavir 62 virologic 62 NNRTI 62 ACR# responses 62 annualized relapse 62 mg dose 62 tipranavir ritonavir 62 lopinavir r 61 seroconverted 61 CD4 + cell 61 enfuvirtide 61 HbA1C 61 CR nPR 61 pCR 61 #mg BID [001] 61 atazanavir 61 mg ustekinumab 61 mg QD 61 atazanavir ritonavir 61 plasma HCV RNA 61 NRTI 61 antiretroviral naive 61 HBeAg 61 undetectable viral 61 % CI #.#-#.# [003] 61 serum phosphorus 61 infliximab 61 mg kg dose 61 antiretroviral regimen 61 oxycodone CR 61 darunavir ritonavir 61 cART 61 lopinavir 61 peg IFN 60 achieved sustained virologic 60 adefovir treated 60 seropositive patients 60 mcg dose 60 mesalamine granules 60 CIMZIA TM 60 APTIVUS r 60 peginterferon alfa 2b 60 glycated hemoglobin levels 60 mcg BID 60 cells/mm3 60 certolizumab 60 valacyclovir 60 dapagliflozin plus 60 undetectable hepatitis C 60 tenofovir emtricitabine 60 serum HCV RNA 60 HbA1c 60 serum HBV DNA 60 genotypic resistance 60 lamivudine 60 antiretroviral naïve 60 chlorambucil 60 Peg IFN 60 mg BID 60 tipranavir r 60 hemoglobin A1c levels 60 BARACLUDE ® 60 ABC/3TC 60 HCV infected 60 ribavirin RBV 60 LEXIVA 60 clodronate 60 clinically meaningful improvement 60 antibody titer 60 pegylated interferon alpha 60 lumbar spine BMD 60 nevirapine Viramune 60 ritonavir boosted 59 indinavir 59 SCIg 59 plus methotrexate 59 undetectable virus HCV 59 lamivudine refractory patients 59 pegylated interferon 59 cEVR 59 COMBIVIR 59 HBeAg positive patients 59 HBeAg positive 59 lopinavir ritonavir 59 genotype 1b 59 virologically 59 nelfinavir 59 boosted protease inhibitor 59 raltegravir 59 mRCC 59 Virologic failure 59 TMC# r 59 baseline HbA1c 59 virologically suppressed 59 PSA nadir 59 urate lowering therapy 59 plasma uric acid 59 log# 59 A1C levels 59 recurrent VTE 59 cytogenetic response 59 amoxicillin clavulanate 59 CR CRu 59 placebo dexamethasone 59 log# copies mL 59 mucosal healing 59 tamoxifen therapy 59 timepoint 59 mcg kg 59 virologic breakthrough 58 remission CR 58 null responders 58 hepatitis C genotype 58 g dL 58 HAART 58 low dose Iluvien 58 HAART regimen 58 peg interferon 58 mcg albinterferon alfa 2b 58 PegIFN RBV 58 EDSS score 58 lopinavir r arm 58 baseline CD4 58 ALND 58 HbA 1c 58 RNA copies mL 58 Median survival 58 recurrent genital herpes 58 HCV genotype 58 serum testosterone 58 endoscopic remission 58 viremia 58 achieved sustained virological 58 8mg/kg 58 Viral load 58 achieve sustained virologic 58 NATRECOR ® 58 Kaplan Meier analysis 58 ertapenem 58 EDSS scores 58 β blockers 58 achieved PASI 58 octreotide LAR 58 FOLFOX4 58 -#.# log# 58 darunavir r 58 noninferiority 58 pegylated interferon alfa 58 PREZISTA rtv 57 gout flares 57 plus dexamethasone 57 Cmax 57 #mg QD [001] 57 rapid virological response 57 rimonabant #mg 57 zidovudine lamivudine 57 IV bisphosphonates 57 Viread Emtriva 57 #mg QD [002] 57 response CCyR 57 NRTIs 57 GnRH agonist 57 pyrazinamide 57 nucleoside naive patients 57 cells uL 57 tumor shrinkage 57 REYATAZ r arm 57 mycophenolate mofetil 57 d4T 57 locoregional disease 57 plus MTX 57 HBeAg negative patients 57 saquinavir 57 Free Survival PFS 57 ALT normalization 57 ng dL 57 treatment naļve 57 anthracycline taxane 57 corticosteroid dose 57 TMC# [001] 57 relapsed MM 57 virologic responses 57 free survival PFS 57 rilpivirine 57 tapentadol ER 57 5-FU/LV 57 lamivudine monotherapy 57 neutrophil counts 57 resected pancreatic cancer 57 NPH insulin 57 ACR Pedi 57 HPV-#/# 57 evaluable 57 abacavir 57 anagrelide 57 R# #mg BID 57 administered subcutaneously 57 FTC TDF 57 ug dose 57 placebo 57 decitabine 57 ritonavir boosted lopinavir 57 comparator arm 57 CRp 57 mL/min/#.# m 2 57 EGFR TKI 57 DAS# remission 57 ISENTRESS 57 HAART regimens 57 VELCADE melphalan 57 #mg dose [003] 57 aminotransferase elevations greater 57 FOLFOX6 57 antibody titers 57 CMV disease 57 mg qd 57 dosing cohorts 57 REYATAZ 57 creatinine clearance 57 evaluable patients 57 alfa 2a 57 prior chemotherapy regimens 57 VIRAMUNE 57 Engerix B 57 efavirenz EFV 57 CMV infection 57 amprenavir 57 mg/m2 dose 57 #mg/day [001] 57 HIV uninfected 57 dalteparin 57 exemestane 57 fasting triglyceride levels 57 BENICAR HCT 56 binary restenosis 56 Raptiva r 56 NATRECOR R 56 anti HBs 56 MCyR 56 definite stent thrombosis 56 #.#ng/ml 56 #mg/day [002] 56 severe neutropenia 56 morphometric vertebral fractures 56 biochemical recurrence 56 incontinence episodes 56 Elitek 56 fluvastatin 56 pegylated interferon alfa 2a 56 ACR# [002] 56 HBeAg negative 56 pegIFN 56 comparator PI r 56 statistical significance p 56 REYATAZ r 56 serum potassium 56 Hb levels 56 azathioprine 56 active comparator 56 FluCAM 56 nitazoxanide 56 prospectively defined 56 inactive placebo 56 atorvastatin #mg 56 3TC lamivudine Epivir 56 telbivudine 56 plus ribavirin 56 neoadjuvant chemotherapy 56 mcg doses 56 anastrozole 56 COPEGUS 56 goserelin 56 antiretroviral therapy 56 serum urate 56 Median PFS 56 μg dose 56 baseline LDH 56 serum phosphate 56 RECIST criteria 56 MADRS score 56 alanine aminotransferase ALT 56 cells μL 56 R0 resection 56 receiving VICTRELIS 56 peginterferon alfa 56 rizatriptan 56 metastatic CRC 56 AZT zidovudine Retrovir 56 plasma concentrations 56 μmol L 56 oral rivaroxaban 56 nucleoside naive 56 dose cohort 56 PEG Interferon alfa 56 liver histology 56 microliter 56 Doxil ® 56 Aptivus ® 56 IELT 56 nadir CD4 cell 56 doxorubicin docetaxel 56 anemia hemoglobin 56 INTELENCE 56 locoregional recurrence 56 DAS# [002] 56 achieving PASI 56 mg doses 56 HBsAg 56 eosinophil count 56 zoledronic acid 55 rFVIIa 55 progression TTP 55 seropositive 55 aged ≥ 55 ibandronate 55 elevated ALT 55 low dose ritonavir 55 CCR5 tropic HIV 55 noninferior 55 CIN3 55 PEG IFN 55 serum clusterin levels 55 degarelix 55 neoadjuvant therapy 55 #mg dose [001] 55 achieved CCyR 55 heavily pretreated 55 3mg/kg 55 cobicistat 55 mg RDEA# 55 underwent liver transplantation 55 Copegus ribavirin 55 OADs 55 dacarbazine 55 mg TID 55 recurrent glioblastoma multiforme 55 adjunctive placebo 55 #mg BID [003] 55 seropositivity 55 bisphosphonate therapy 55 lymphocyte count 55 postoperative chemotherapy 55 log# IU mL 55 advanced adenomas 55 dose GATTEX 55 imatinib 55 bendamustine 55 vicriviroc 55 unboosted 55 piperacillin tazobactam 55 chlamydial infection 55 sUA levels 55 #mg ATC 55 d4T stavudine Zerit 55 LVEF 55 insulin detemir 55 PSADT 55 mcg Albuferon 55 advanced adenoma 55 baseline A1C 55 peginterferon alpha 2a 55 ACTEMRA TM 55 AVODART 55 docetaxel chemotherapy 55 low dose cytarabine 55 ALT flares 55 CrCl 55 carboplatin paclitaxel 55 aromatase inhibitor 55 REYATAZ ® 55 cells mcL 55 #mg doses [002] 55 mmol l 55 interferon ribavirin 55 ULORIC 55 RRMS patients 55 mg simvastatin 55 nadolol 55 NRTI backbone 55 TPV r 55 mitoxantrone 55 infliximab monotherapy 55 HIV seroconversion 55 chemo radiotherapy 55 oral ridaforolimus 55 antiretroviral therapy ART 55 DMARD 55 serum uric acid 55 mg dL 55 steroid dexamethasone 55 q#h 55 atazanavir sulfate 55 seronegative 55 CIMZIA ™ 55 CD4 count 55 HbA 1c levels 55 Index CDAI 55 % CI #.#-#.# [006] 55 FOLFIRINOX 55 paricalcitol 55 ng ml 55 Viread Emtriva Sustiva 55 fondaparinux 55 oral olanzapine 55 viral kinetics 55 nilotinib 55 intravenous bisphosphonates 55 ddI 55 mg Lucentis 55 tamsulosin 55 abatacept 55 HbA1C levels 55 chronic HCV genotype 55 abnormal mammogram 55 plus OBT 55 statistically significant p 55 HCV replicon 55 dose dexamethasone 55 HBV infections 55 oral diclofenac 55 hemoglobin A1c HbA1c 55 acute gout flares 55 relapsed AML 55 imatinib therapy 55 adenoma recurrence 55 subcutaneous enoxaparin 55 nonnucleoside reverse transcriptase inhibitors 55 chronic HCV infection 55 intraocular inflammation 55 Durezol 55 doripenem 55 canakinumab 55 NRTI sparing 55 QTcF 55 receiving antiretroviral therapy 55 elevated transaminases 55 hsCRP levels 55 pegfilgrastim 55 antiviral therapy 55 interferon alfa 54 ribavirin 54 Recurrence Score 54 IFN alfa 54 Flu Cy 54 #.#mg/dL 54 budesonide pMDI 54 partial remissions 54 q8h 54 serum phosphate levels 54 Crohn Disease Activity 54 dose ritonavir 54 symptomatic intracerebral hemorrhage 54 receiving golimumab 54 postmenopausal osteoporotic women 54 antihypertensive therapy 54 adefovir dipivoxil 54 CIMZIA TM certolizumab pegol 54 tocilizumab 54 HIV infected 54 spontaneous preterm delivery 54 apremilast 54 dasatinib 54 UGT#A# * 54 antihypertensive medications 54 serum urate levels 54 serum testosterone levels 54 weekly subcutaneous injections 54 complete remissions 54 serum concentrations 54 ethambutol 54 microgram dose 54 PREZISTA ritonavir 54 virologic failures 54 pegylated interferon alfa 2b 54 KRAS mutations occur 54 solifenacin 54 baminercept 54 Victoza R 54 dose cohorts 54 elevated serum creatinine 54 PREZISTA r arm 54 naïve HCV 54 hypogonadal men 54 serum creatinine levels 54 Median progression 54 antiviral efficacy 54 moderate renal impairment 54 tumor recurrence 54 interferon alfa 2b 54 dosage regimens 54 CDAI 54 osteoporotic fracture 54 relapsing MS 54 telaprevir dosed 54 TEAEs 54 Kaplan Meier estimate 54 posaconazole 54 nmol liter 54 REYATAZ ritonavir 54 pg mL 54 azacitidine 54 cytogenetic responses 54 NNRTIs 54 REYATAZ R 54 achieved statistical significance 54 lymphocytosis 54 HCV RESPOND 2 54 BENICAR 54 antibody responses 54 cabazitaxel 54 posttreatment 54 asthma exacerbation 54 hemoglobin concentrations 54 potent antiretroviral therapy 54 eGFR 54 dose colchicine 54 clinically meaningful 54 IPSS 54 BARACLUDE 54 rifapentine 54 antiretroviral ARV therapy 54 ritonavir boosted protease inhibitor 54 flutamide 54 palivizumab 54 lopinavir ritonavir Kaletra 54 HCV antibody 54 Hepsera 54 Psoriasis Area 54 recurrent atrial fibrillation 54 mg d 54 mL/min/#.# m2 54 splenectomized patients 54 FOLFIRI 54 alemtuzumab treated 54 Virologic 54 chronic HBV 54 concomitant antibiotics 54 adalimumab Humira 54 trastuzumab Herceptin ® 54 sitagliptin 54 ARB telmisartan 54 g dl 54 serum ALT 54 premenopausal 54 etravirine 54 biphasic insulin aspart 54 androgen deprivation 54 glycated hemoglobin HbA1c 54 patients evaluable 54 CC genotype 54 trabedersen 54 FOLPI 54 STELARA ® 54 desvenlafaxine succinate 54 suppressive therapy 54 insulin glargine 54 Darunavir 54 ATACAND 54 dose clopidogrel 54 FOLFOX 54 Pegasys peginterferon alfa 2a 54 glargine 54 tolterodine ER 54 APTIVUS 54 pegylated liposomal doxorubicin 54 CDAI score 54 chemoradiotherapy 54 relapsed SCLC 54 gout flare 54 adjuvant radiation 54 alteplase 54 fragility fracture 54 docetaxel 54 null responder HCV 54 serodiscordant couples 54 MELD scores 54 IRLS score 54 microg 54 Sprycel dasatinib 54 Ishak fibrosis score 54 APTIVUS R 54 ketoconazole 54 chronic HCV 54 osteopenic 54 Adalimumab 54 protease inhibitors PIs 54 CANCIDAS 54 severe rotavirus gastroenteritis 54 SHBG levels 54 baseline FEV1 54 % Confidence Interval 54 #mg BID [002] 54 Response Evaluation Criteria 54 transaminase elevations 54 fasting plasma glucose FPG 54 lipid lowering medications 54 HCV infection 54 1mg dose 54 JANUVIA 53 RLAI 53 mg tid 53 pomalidomide 53 tenofovir FTC 53 nmol L 53 platelet counts 53 OGTT 53 PegIntron 53 topotecan 53 lanthanum carbonate 53 mg/m2/day 53 CsA 53 bortezomib refractory 53 aspartate aminotransferase AST 53 #mg/kg [002] 53 diuretic chlorthalidone 53 oral allopurinol 53 plus prednisone prednisolone 53 forodesine 53 efavirenz 53 inhaled steroid 53 ng mL 53 glycosylated hemoglobin 53 peginterferon alfa 2a #KD 53 mg subcutaneously 53 poor metabolizers 53 alanine aminotransferase 53 anti TNF 53 Baseline characteristics 53 clinically meaningful improvements 53 mitoxantrone plus 53 DAS# CRP 53 methotrexate therapy 53 febrile neutropenia 53 #mg q8h 53 cytarabine daunorubicin 53 oral FTY# 53 mCi m 2 53 nadroparin 53 nonvertebral fractures 53 BCG vaccinated 53 INC# 53 saline placebo 53 iPrEx study 53 mIU L 53 A1C 53 hematologic toxicity 53 endometrial thickness 53 elvucitabine 53 benazepril 53 venlafaxine XR 53 Rapid Virological Response 53 gemcitabine carboplatin 53 systolic dysfunction 53 oral prednisone 53 cilostazol 53 #ng/ml 53 Solid Tumors RECIST 53 combination antiretroviral therapy 53 mCRC patients 53 mEq L 53 pegylated interferon alpha 2a 53 #mmHg [001] 53 Fludara 53 β blocker 53 dose regimens 53 INVIRASE 53 PROMACTA 53 protease inhibitor mutations 53 FOLPI regimen 53 Telbivudine 53 REMICADE ® 53 elevated LDL cholesterol 53 STELARA 53 severe exacerbations 53 adriamycin 53 ofpatients 53 creatinine ratio 53 anthracycline containing 53 pentoxifylline 53 mutated KRAS 53 underwent resection 53 standard chemotherapy regimen 53 nonresponders 53 tenecteplase 53 KRAS mutant tumors 53 adjuvant tamoxifen 53 prednisone prednisolone 53 placebo fluoxetine 53 heavily pretreated patients 53 radiographic progression 53 Celsentri Selzentry 53 -#.# log# copies mL 53 isoniazid 53 HCV viral 53 discontinued Viread 53 unprotected anal sex 53 lenalidomide Revlimid R 53 patients coinfected 53 HOMA IR 53 viral kinetic 53 TRIZIVIR 53 Traficet EN 53 elevated troponin 53 highly emetogenic 53 #mmHg [002] 53 unfractionated heparin 53 caspofungin 53 operable breast cancer 53 Solid Tumors criteria 53 NAbs 53 BCVA 53 nondiabetic patients 53 relapsers 53 COPAXONE R 53 dose escalation phase 53 XIENCE V PROMUS Stent 53 lipid lowering therapy 53 RBC transfusions 53 nonadherent 53 53 #mg/m# [002] 53 treatment naive genotype 53 4mg/kg 53 creatinine levels 53 hydroxyvitamin D levels 53 platelet reactivity 53 pmol L 53 oral antidiabetic medication 53 rFSH 53 NLX P# 53 FDA defined valvulopathy 53 elevated CRP 53 angiographic restenosis 53 subtrochanteric 53 timepoints 53 eribulin 53 prior relapsers 53 esomeprazole 53 histologically confirmed 53 radioiodine therapy 53 NRTI resistance 53 sunitinib 53 hip BMD 53 serum PSA 53 inadequate glycemic 53 abdominal hysterectomy 53 P = .# 53 #.#/#.# mmHg [001] 53 COPEGUS ribavirin 53 EBRT 53 titers 53 secondary efficacy endpoint 53 iPTH 53 vertebral fracture 53 metastatic renal cell carcinoma 53 teriflunomide 53 tenofovir 53 divalproex sodium 53 K#N 53 nicardipine 53 superinfection 53 dose cytarabine 53 metastatic RCC 53 valopicitabine 53 microalbumin test 53 dose regimen 53 secondary endpoint 53 titrated glipizide 53 etanercept 53 oxcarbazepine 53 beta blocker therapy 53 ritonavir boosted atazanavir 53 hemagglutination inhibition 53 severe renal impairment 53 ARICEPT 53 DAPT 53 dosing intervals 53 epithelial ovarian cancer 53 unprotected receptive anal 53 co trimoxazole 53 stavudine d4T 53 relapsed ovarian cancer 53 MAGE A3 ASCI 53 NovoLog ® Mix 53 LTBI 53 HSCT 53 cervical intraepithelial neoplasia 53 estimated GFR 53 CK # plasma concentrations 53 coinfected patients 53 Sustained Virological Response 53 postintervention 53 combination REBETOL PEG 53 remission induction 53 infliximab therapy 53 abnormal Pap test 53 femoral neck BMD 53 #mg/m# [001] 52 quetiapine 52 monotherapy 52 mg dl 52 KOMBIGLYZE XR 52 pegylated interferon peg IFN 52 telaprevir 52 albumin excretion 52 XELOX 52 systolic BP 52 PRADAXA #mg 52 LMWH 52 Index CDAI score 52 PASI score 52 inert placebo 52 invasive aspergillosis 52 low expressors 52 ritonavir 52 mcg mL 52 pg ml 52 DOXIL 52 peginterferon alfa 2a Pegasys 52 daunorubicin 52 mg m² 52 macroalbuminuria 52 Reverset 52 pyridostigmine 52 interquartile range 52 relapsed Hodgkin lymphoma 52 locoregional 52 postoperative mortality 52 ACR# ACR# 52 posttransplant 52 RESIST studies 52 ketorolac 52 Naive Patients 52 metastatic renal cell 52 aldosterone antagonist 52 genital ulcers 52 postvaccination 52 odanacatib 52 IFN α 52 interferon alfa 2a 52 plus gemcitabine 52 peak plasma concentrations 52 initiating HAART 52 Lantus ® 52 methotrexate monotherapy 52 cotrimoxazole prophylaxis 52 statistically significant p = 52 undergone splenectomy 52 boosted atazanavir 52 dexamethasone Decadron 52 intracranial hemorrhage ICH 52 preintervention 52 neutrophil count 52 #.#g/day 52 serum phosphorous 52 metformin sulfonylurea 52 Lupuzor ™ 52 antimicrobial prophylaxis 52 #Gy 52 tamoxifen 52 evaluating tivozanib 52 Pegylated Liposomal Doxorubicin 52 oblimersen 52 orchiectomy 52 secondary efficacy endpoints 52 mg eq 52 stavudine 52 placebo p = 52 precancerous cervical lesions 52 ETDRS 52 disease progression 52 trials RCTs 52 ejection fractions 52 tiotropium 52 HAM D# scores 52 Lamictal XR 52 lipid lowering drugs 52 asymptomatic carotid stenosis 52 neoadjuvant 52 estimated glomerular filtration 52 mITT population 52 QTc prolongation 52 5-fluorouracil/leucovorin 52 imipenem 52 ipsilateral stroke 52 maximal dose 52 oral bisphosphonates 52 DMARDs 52 tenofovir DF 52 #OHD levels 52 preoperative chemotherapy 52 Pred Forte 52 antiandrogen 52 adjunctive ABILIFY 52 serum IGF 52 AZOR 52 prevalent vertebral fracture 52 CSBMs 52 YERVOY 52 ritonavir Norvir 52 interferon beta therapy 52 postexposure prophylaxis 52 aromatase inhibitor therapy 52 leukocyte count 52 durable remissions 52 BRAF mutation 52 recurrent GBM 52 spontaneous preterm birth 52 pioglitazone 52 MabCampath 52 inecalcitol 52 adjuvant therapy 52 interferon therapy 52 hours postdose 52 squamous histology 52 % CI #.#-#.# [008] 52 FIRMAGON 52 Natalizumab 52 boceprevir 52 receiving APTIVUS r 52 A1c 52 neurologic progression 52 Epivir 52 NNRTI resistant virus 52 Combination therapy 52 Sustained virologic response 52 HIV infection 52 elagolix 52 MMSE score 52 ng dl 52 maximal doses 52 stage IIIb IV 52 p = .# [002]

Back to home page